According to Reuters, a federal appeals court has declined to review an order certifying a class action by purchasers of the acne medication Solodyn alleging Medicis Pharmaceutical Corp sought to delay the launch of generic versions of the drug in violation of antitrust laws.
The 1st US Circuit Court of Appeals in Boston on Monday, February 12, declined to take up the appeal by Medicis, a unit of Valeant Pharmaceuticals International Inc, and generic drugmaker Impax Laboratories Inc, before the case goes to trial on March 12.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
